AIkido Pharma Inc. [NASDAQ: AIKI] gained 4.50% on the last trading session, reaching $1.16 price per share at the time. The company report on July 9, 2020 that AIkido Pharma Inc. Announces Key Progress in Computational Approaches to Identify Virus Treatments, Including Coronavirus.
Research identified human protein complex that is important for viral replication.
AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today provided an update on its effort to identify compounds to potentially address the COVID-19 pandemic. As previously announced, on April 13, 2020, AIkido executed a Master License Agreement with the University of Maryland, Baltimore (“UMB”), covering certain antiviral compounds discovered by UMB.
AIkido Pharma Inc. represents 34.92 million in outstanding shares, while the company has a total market value of $40.84 million with the latest information. AIKI stock price has been found in the range of $1.06 to $1.19.
If compared to the average trading volume of 4.45M shares, AIKI reached a trading volume of 1982480 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about AIkido Pharma Inc. [AIKI]:
The Average True Range (ATR) for AIkido Pharma Inc. is set at 0.13, with the Price to Sales ratio for AIKI stock in the period of the last 12 months amounting to 4538.18. The Price to Book ratio for the last quarter was 0.51, with the Price to Cash per share for the same quarter was set at 0.47.
Trading performance analysis for AIKI stock
AIkido Pharma Inc. [AIKI] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.75. With this latest performance, AIKI shares gained by 30.09% in over the last four-week period, additionally plugging by 1.00% over the last 6 months – not to mention a drop of -45.55% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AIKI stock in for the last two-week period is set at 62.94, with the RSI for the last a single of trading hit 62.30, and the three-weeks RSI is set at 61.38 for AIkido Pharma Inc. [AIKI]. The present Moving Average for the last 50 days of trading for this stock 0.8452, while it was recorded at 1.1540 for the last single week of trading, and 1.0338 for the last 200 days.
AIkido Pharma Inc. [AIKI]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and AIkido Pharma Inc. [AIKI] shares currently have an operating margin of -63166.67. AIkido Pharma Inc.’s Net Margin is presently recorded at -46477.78.
Return on Total Capital for AIKI is now -50.24, given the latest momentum, and Return on Invested Capital for the company is -36.97. Return on Equity for this stock declined to -36.97, with Return on Assets sitting at -34.10.
Reflecting on the efficiency of the workforce at the company, AIkido Pharma Inc. [AIKI] managed to generate an average of -$1,394,333 per employee.AIkido Pharma Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 26.90 and a Current Ratio set at 26.90.
An analysis of insider ownership at AIkido Pharma Inc. [AIKI]
There are presently around $0 million, or 18.10% of AIKI stock, in the hands of institutional investors. The top three institutional holders of AIKI stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 210,758, which is approximately 250.248% of the company’s market cap and around 5.64% of the total institutional ownership; TWO SIGMA SECURITIES, LLC, holding 25,694 shares of the stock with an approximate value of $30000.0 in AIKI stocks shares; and SUSQUEHANNA INTERNATIONAL GROUP, LLP, currently with $26000.0 in AIKI stock with ownership of nearly New of the company’s market capitalization.
Positions in AIkido Pharma Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 13 institutional holders increased their position in AIkido Pharma Inc. [NASDAQ:AIKI] by around 241,226 shares. Additionally, 5 investors decreased positions by around 22,415 shares, while 2 investors held positions by with 58,583 shares. The mentioned changes placed institutional holdings at 322,224 shares, according to the latest SEC report filing. AIKI stock had 11 new institutional investments in for a total of 90,150 shares, while 4 institutional investors sold positions of 21,904 shares during the same period.